Skip to main content

Table 2 Demographic and Baseline Characteristics by WHO Functional Class and Treatment Group (Primary Analysis Set)

From: Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension

  Combination Therapy Pooled Monotherapy Ambrisentan Monotherapy Tadalafil Monotherapy Total (N = 500)
(n = 253) (n = 247) (n = 126) (n = 121)
Baseline Functional Class FC II FC III FC II FC III FC II FC III FC II FC III FC II FC III
Patients (n) 76 177 79 168 38 88 41 80 155 345
Age, years
 Mean 50 56 53 55 52 55 54 55 52 56
 SD 16 13 15 15 15 14 15 15 15 14
Female 66% 78% 80% 82% 82% 78% 78% 85% 73% 80%
North Americab 53% 43% 53% 42% 53% 35% 54% 49% 53% 42%
Type of PAH
 Idiopathic/ Heritable PAH 53% 53% 58% 59% 58% 60% 59% 58% 55% 56%
 PAH associated with connective tissue diseasea 34% 44% 28% 37% 32% 36% 24% 38% 31% 40%
 PAH associated with congenital heart diseasea 7% 0 4% 1% 3% 0 5% 1% 5% < 1%
 Hemodynamic variables (mean ± SD)
  Right atrial pressure (mmHg) N = 76
7 ± 4
N = 176
8 ± 5
N = 79
7 ± 5
N = 167
8 ± 5
N = 38
7 ± 4
N = 87
8 ± 5
N = 41
8 ± 5
N = 80
9 ± 5
N = 155
7 ± 4
N = 343
8 ± 5
  Pulmonary artery pressure (mmHg) N = 76
47 ± 14
N = 177
49 ± 12
N = 79
46 ± 12
N = 168
51 ± 12
N = 38
47 ± 13
N = 88
52 ± 12
N = 41
45 ± 12
N = 80
50 ± 13
N = 155
46 ± 13
N = 345
50 ± 12
  Pulmonary capillary wedge pressure (mmHg) N = 72
9 ± 3
N = 172
8 ± 3
N = 77
9 ± 3
N = 159
9 ± 3
N = 38
8 ± 3
N = 83
9 ± 3
N = 39
10 ± 3
N = 76
9 ± 4
N = 149
9 ± 3
N = 331
9 ± 3
  Cardiac index (L/min/m2) N = 73
2.5 ± 0.7
N = 176
2.4 ± 0.6
N = 79
2.6 ± 0.8
N = 164
2.4 ± 0.6
N = 38
2.7 ± 0.7
N = 87
2.3 ± 0.6
N = 41
2.5 ± 0.9
N = 77
2.4 ± 0.7
N = 152
2.5 ± 0.8
N = 340
2.4 ± 0.6
  Pulmonary vascular resistance, c (dyne/sec/cm5) N = 76
740 ± 370
N = 177
860 ± 500
N = 79
690 ± 320
N = 168
890 ± 420
N = 38
690 ± 240
N = 88
920 ± 420
N = 41
700 ± 350
N = 80
850 ± 430
N = 155
720 ± 340
N = 345
870 ± 460
  1. FC Functional class, PAH Pulmonary arterial hypertension, SD Standard deviation, WHO World Health Organization
  2. aPost-hoc summary; bNorth America (vs. Rest of World, mostly Western Europe), cValues have been rounded to two significant digits for ease of comparison